Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as reboxetine monotherapy
Reboxetine · 5 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 3 | EXPERIMENTAL | - |
| 4 | SHAM_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Sertraline/[S,S]-Reboxetine-satellite150/4 | EXPERIMENTAL | - |
| Sertraline/[S,S]-Reboxetine-satellite150/6 | EXPERIMENTAL | - |
| sertraline-satellite | ACTIVE_COMPARATOR | - |
| sertraline-main | ACTIVE_COMPARATOR | - |
| Sertraline/[S,S]-Reboxetine-satellite150/2 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Sertraline/[S,S]-Reboxetine-main | EXPERIMENTAL | - |
| [S,S]-reboxetine-main | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| [S,S]-Reboxetine | DRUG | 10 mg oral tablet once a day dosing |
| Placebo | DRUG | 0 mg oral tablet once a day dosing |
| sertraline/[S,S]-reboxetine | DRUG | Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg \[S,S\]-reboxetine for 5 and one half weeks. |
| sertraline | DRUG | Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks. |
| [S,S]-reboxetine monotherapy | DRUG | Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks |
Inclusion Criteria: * Male or female of any race, at least 18 years of age * Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites) Exclusion Criteria: * Patients with other severe pain (e...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Axsome Therapeutics, Inc. | AXSM | 2 | PHASE3 | AXS-14 |
Reboxetine has been studied in major depressive disorder, fibromyalgia, and pain. It is an investigational small molecule being developed by Pfizer, Inc. (NYSE: PFE). Clinical trials have evaluated it both as monotherapy and in combination with sertraline for major depression, and as a treatment for fibromyalgia and pain.
Reboxetine targets SLC6A2, the norepinephrine transporter. It acts as an inhibitor of this transporter. By inhibiting SLC6A2, reboxetine affects norepinephrine reuptake. This target class is consistent with its development in psychiatry and pain-related conditions.
Pfizer, Inc. (NYSE: PFE) is the developer of reboxetine. The company has sponsored clinical trials of the drug in major depressive disorder, fibromyalgia, and pain. Pfizer holds the ticker PFE on the New York Stock Exchange.
Reboxetine is in Phase 2 development overall. One completed trial of [S,S]-reboxetine in fibromyalgia was listed as Phase 3, but the drug is not approved and remains investigational. All three completed trials have finished, and no active trials are ongoing.
Reboxetine has been studied in completed trials including NCT00636246, which compared sertraline-reboxetine combination therapy with sertraline or reboxetine monotherapy in major depression; NCT00612170, a 14-week fibromyalgia study; NCT00357825, a fibromyalgia pain trial; and NCT00288652, a dose-range finding trial in pain.
Yes, [S,S]-reboxetine is an alternative name for reboxetine. Other names used in study titles include [S,S]-reboxetine monotherapy and reboxetine monotherapy. These refer to the same investigational compound developed by Pfizer for major depressive disorder, fibromyalgia, and pain.